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INTRODUCTION 
 
Subclinical hypothyroidism (SH) is characterized by an elevated serum 
concentration of thyroid stimulating hormone (TSH) and normal serum 
concentration of free thyroxine (FT4) in the presence or absence of symptoms1. 
This biochemical state has been given a variety of other names, including 
mild thyroid failure, as well as compensated, early, late, minimally symptomatic, 
and pre-clinical hypothyroidism 2,3. 
Although the term subclinical hypothyroidism is widely used, mild 
hypothyroidism may be more appropriate4.  
Subclinical hypothyroidism is a common disorder with prevalence ranging 
from 1–10% of the, mostly adult, population 5-9, with the highest rate approaching 
26% in elderly women 6,10,11. In a study conducted in Saudi Arabia the prevalence 
in elderly women more than 50 years of age reached 35%. 
Clinical manifestations of subclinical hypothyroidism include abnormal 
lipid metabolism 12-14, cardiac dysfunction 15,16, and neurological and mental 
dysfunction 17, and several cross-sectional studies have suggested that it confers an 
elevated risk of atherosclerosis and coronary heart disease 11,18. However, neither 
of these associations has been confirmed by others 19,20. This discrepancy may 
reflect the small size of the studies or participation in studies limited to one sex.  
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Also, only few longitudinal studies have been conducted. The relationship 
between subclinical hypothyroidism and cardiovascular disease is therefore 
controversial, and possible outcomes of the condition remain unclear. Importantly, 
several previous studies suggesting that thyroid autoimmunity is a risk factor for 
coronary heart disease 18,21,22 remain surrounded by controversy 20,23. 
Women with subclinical hypothyroidism did not differ from controls with 
regard to BMI, hypertension, and diabetes mellitus in previous studies11,24.  
The present study has been performed to estimate the prevalence of 
subclinical hypothyroidism and its relation to hypertension, diabetes, and ischemic 
heart disease among women above the age of 50 years attending Medical 
outpatient clinic at Government Stanley Medical College and Hospital. 
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AIM OF THE STUDY 
 
 To estimate the prevalence of Subclinical Hypothyroidism among women 
above the age of 50 years. 
 To study the relationship of Subclinical Hypothyroidism to Hypertension, 
Diabetes Mellitus and Ischemic Heart Disease in those patients. 
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REVIEW OF LITERATURE 
 
The thyroid gland produces two related hormones, thyroxine (T4) and 
triiodothyronine (T3). Acting through nuclear receptors, these hormones play a 
critical role in cell differentiation during development and help maintain 
thermogenic and metabolic homeostasis in the adult. Disorders of the thyroid 
gland result primarily from autoimmune processes that either stimulate the 
overproduction of thyroid hormones (thyrotoxicosis) or cause glandular 
destruction and hormone deficiency (hypothyroidism). 
 
THYROID GLAND 
Embryological development 
Thyroid is the first endocrine glandular tissue to appear in mammalian 
development. In humans the thyroid gland arises from two distinct regions of the 
endodermal pharynx. The median anlage arises from the midline of the anterior 
pharyngeal floor between branchial arches 1 and 2 and is visible by day 17 of 
gestation. In contrast, the two lateral anlage (ultimobranchial bodies) develop as 
caudal projections from the fourth or fifth pharyngeal pouches. The growth and 
descent of the median anlage is accompanied by the development of a stalk 
(thyroglossal duct) which keeps it attached to its pharyngeal floor origin. The 
subsequent obliteration of the lumen of the duct is associated with lateral 
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expansion of the anlage and the beginnings of the formation of the characteristic 
bi-lobed structure of the thyroid. Simultaneously with the descent of the median 
anlage, the ultimobranchial bodies separate from the pharyngeal pouches and fuse 
with the lateral parts of the median anlage. Degeneration of the attachments of the 
ultimobranchial bodies to their pharyngeal origins is accompanied by proliferation 
of median anlage cells which surround the tissues of the lateral anlage. This 
association between the median and lateral anlage is complete by the ninth week 
of gestation, at which stage the thyroid has its characteristic shape. The 
contribution of the lateral anlage tissues to the formation of functioning thyroid 
tissue is minimal and their main contribution is in the provision of parafollicular 
calcitonin-secreting (C) cells. 
 
Structure 
The thyroid gland consists of two lobes connected by an isthmus, with the 
adult normal gland in an iodine replete population weighing 15-20 g. The gland is 
attached to the anterior and lateral aspects of the trachea by loose connective tissue 
such that the isthmus lies just below the cricoid cartilage. The recurrent laryngeal 
nerves lie in the grooves between the lateral lobes and the trachea and the lateral 
extent of the thyroid lobes are marked by the carotid sheaths and 
sternocleidomastoid muscles. The well-vascularized gland is supplied by the 
superior and inferior thyroid arteries on each side. The gland has both adrenergic 
and cholinergic innervations. 
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The basic functional unit of the thyroid gland is the follicle. These hollow, 
spherical structures ranging in size from 15 to 500 µm in diameter are surrounded 
by a basement membrane. The wall of the unit is made up of a single layer of 
thyroid follicular cells, which are cuboidal when quiescent. The lumen of the 
follicle contains the proteinaceous colloid which is normally the major constituent 
of the thyroid mass and serves as the primary site of storage of thyroglobulin 
secreted by the thyroid follicular cells. The rich capillary network surrounding the 
follicles and the high blood flow through the gland ensure easy access of thyroid 
hormone to the circulation. Interspersed between the thyroid follicles are the 
parafollicular C cells which secrete calcitonin. 
 
THYROID HORMONES 
Thyroid hormone synthesis and secretion 
Synthesis of adequate quantities of thyroid hormone necessitates more 
rapid entry of iodide into thyroid follicular cells than is possible by passive 
diffusion from the extracellular fluid. A poorly characterized (trapping) 
mechanism ensures that sufficient iodide substrate is available for hormone 
formation. This process is enhanced by thyroid stimulating hormone, thyrotrophin 
(TSH) and is responsive to the glandular content of organic iodine. The 
mechanism for concentrating iodide is shared by the other monovalent anions 
perchlorate and pertechnetate. Glandular tissue in the salivary glands and gastric 
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mucosa, tissues of endodermal origin, have a similar capacity for concentrating 
iodide. 
Once iodide is trapped within the thyroid follicular cell it is rapidly 
oxidized in the presence of hydrogen peroxide by the enzyme thyroid peroxidase, 
a 933 amino acid, membrane bound, glycosylated, heme-containing protein. 
Oxidation is followed by the incorporation of the resulting reactive intermediate 
into the tyrosine residues of thyroglobulin (iodide organification). Thyroid 
peroxidase, which is central to this process, is predominantly localized on the 
apical border of the thyroid cell and this location suggests that it is at this interface 
between the follicular cell apical surface and the colloid that organification occurs. 
Oxidation and organification of iodide result in the formation of 
hormonally inactive iodotyrosines (monoiodotyrosine and diiodotyrosine). The 
coupling of these iodinated tyrosines leads to the formation of the hormonally 
active iodothyronines T4 and T3. The synthesis of T4 results from the fusion of 
two molecules of diiodotyrosine, whereas the formation of T3 results from the 
coupling of a molecule of monoiodotyrosine with one of diiodotyrosine. Thyroid 
peroxidase plays a key role in thyroid hormone biosynthesis, not only in the 
catalysis of the iodination of tyrosyl residues in thyroglobulin but also in the 
coupling of iodotyrosyl residues in thyroglobulin to form T4 and T3. 
Thyroglobulin, the main precursor of thyroid hormones is a large 
glycoprotein molecule present in the follicular luminal colloid in multiple forms, 
with the most prevalent and the major source of thyroid hormone being the 19S 
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molecule with a molecular size of 660 kDa. The sites in the molecule for thyroid 
hormone formation have been identified. There are approximately three to four T4 
molecules per mole of human thyroglobulin under conditions of normal 
iodination, but only one in five molecules of human thyroglobulin contains a T3 
residue. Thyroglobulin synthesis in the thyroid follicular cell is the same as that 
for other glycoproteins. Following transcription and processing of thyroglobulin 
mRNA and its ribosomal translation, the resulting polypeptide chain is extruded 
into the endoplasmic reticulum and glycosylated during transport to the Golgi 
apparatus. Packaging of the thyroglobulin into exocytotic vesicles in the Golgi 
apparatus then allows the transport of the protein in these vesicles, which also 
contain membrane-bound thyroid peroxidase, to the apical surface of the follicular 
cell, where the contents are released into the colloid-containing follicular lumen. 
The process of thyroglobulin biosynthesis and exocytosis is regulated by TSH. 
For thyroid hormone to be secreted into the circulation, thyroglobulin from 
the large colloid reservoir needs to re-enter the thyroid follicular cell where it 
undergoes proteolytic cleavage with the release of T4 and T3, which leave the 
thyroid follicular cell at its basal surface to enter the capillary circulation. This 
process is activated by TSH with the formation of pseudopodia induced on the 
apical surface of the follicular cells which engulf colloid to produce colloid-
containing endocytotic vesicles within the follicular cell. The subsequent fusion of 
enzyme-containing lysosomes with these droplets leads to the hydrolysis of 
thyroglobulin and the liberation of the iodotyrosines from the thyroglobulin. 
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REGULATION OF THYROID FUNCTION 
Thyroid hormone synthesis and secretion are closely regulated by 
extrathyroidal (TSH) and intrathyroidal mechanisms. The thyroid participates with 
the hypothalamus and pituitary in a classical feedback control system. Fluctuations 
in hormone secretion are prevented in part by the large intraglandular store of 
hormone which buffers the effects of acute increases or decreases in hormone 
synthesis. Autoregulatory mechanisms within the gland maintain the constancy of 
the intraglandular hormone pool. 
TSH is the major regulator of thyroid structure and function. Its secretion, 
in turn, is regulated by thyrotrophin releasing hormone (TRH) from the 
hypothalamus which stimulates the pituitary thyrotroph to release and later 
synthesize TSH. It is at this level in the feedback system that thyroid hormones act 
to inhibit function. TRH is a tripeptide synthesized by the peptidergic neurones in 
the supraoptic and paraventricular nuclei of the hypothalamus, and is transported 
from them and stored in the median eminence. Thereafter TRH enters the 
hypophyseal portal venous system to act on the pituitary thyrotrophs to release 
TSH. Although TRH and thyroid hormones are the major regulators of TSH 
secretion, somatostatin, dopamine, and pharmacological doses of glucocorticoids 
impair the release of TSH in response to TRH. 
TSH is a glycoprotein hormone secreted by thyrotroph cells of the anterior 
pituitary. It is composed of a 14 kDa α-subunit in common with luteinizing 
hormone, follicle stimulating hormone and human chorionic gonadotropin, and a 
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specific β-subunit. It is secreted in both 1 to 2 hourly pulses and with a circadian 
rhythm which is characterized by a nocturnal surge which precedes the onset of 
sleep. By binding to the TSH receptor on the thyroid follicular cells (one of the 
family of seven-transmembrane spanning G-protein linked receptors), TSH 
activates thyroid function, predominantly through adenylate cyclase. A number of 
key elements of thyroid cell function have been demonstrated to be responsive to 
TSH stimulation; these include iodide transport with both acute and delayed 
effects, iodide organification, the release of thyroglobulin from exocytotic vesicles 
into the follicular lumen, increased pseudopod formation on the apical cell border 
allowing endocytosis of colloid, lysosome maturation and interaction with the 
endocytotic vesicle, thyroid hormone secretion, and, with chronic stimulation, 
hyperplasia and thyroid growth. 
Autoregulatory control mechanisms are assumed to be at work when the 
level of TSH remains constant. In situations of TSH deficiency, variations in 
dietary iodine intake continue to influence iodide transport. The influence of 
iodine on the rate of thyroid hormone synthesis is determined by the amount and 
duration of administration of iodine. With increasing doses of iodide given 
acutely, the initial increase in the organification of iodine is then followed by a 
decrease. This decreasing yield of organic iodine, despite increasing dosage of 
iodide, is termed the acute Wolff-Chaikoff effect. As a result, synthesis of 
hormonally active iodothyronine is abolished and overproduction of thyroid 
hormone is prevented. Chronic repeated lower dose iodide administration allows 
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‘escape’ from this process, thus preventing the development of goitrous 
hypothyroidism. Pharmacological doses of iodine will, in addition, rapidly inhibit 
thyroid hormone release. This acute effect occurs much more rapidly than is seen 
with the Wolff-Chaikoff effect and the mechanism remains uncertain. 
Despite the well-recognized and abundant adrenergic nerve fibre supply to 
the thyroid, the contribution that catecholamines make to thyroid hormone 
production is less well defined. 
 
LABORATORY EVALUATION 
Measurements of thyroid hormones 
The techniques of measurement of thyroid hormones have moved through 
several eras, which began with the measurement of iodine content of serum 
protein (protein bound iodine) as an indirect measure of serum content of T4, 
evolved to competitive binding assays that use the displacement of T4 from 
thyroxine-binding globulin, which, in turn, have been replaced by improved 
immunoassays using highly specific antibodies to T4. Similar immunoassay 
methods have been developed for the measurement of total serum T3. Using such 
assay systems it is possible to establish normal ranges for circulating thyroid 
hormones since these hormone measurements reflect the concentrations of protein-
bound hormone in the blood, they will vary with alterations in thyroid hormone 
binding protein concentrations. In order to overcome these problems, tests 
designed to measure the concentrations of free thyroid hormone levels have been 
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developed. Currently available assays for the assessment of free thyroid hormone 
which are capable of automation and therefore of handling large numbers of 
samples are based either on analogue methodology or methods using two-step or 
labelled antibody immunoassays. Recently electrochemolumences method is used 
to perform thyroid function tests. 
The enhanced sensitivity and specificity of TSH assays have greatly 
improved laboratory assessment of thyroid function. Because TSH levels change 
dynamically in response to alterations of T4 and T3, a logical approach to thyroid 
testing is to first determine whether TSH is suppressed, normal, or elevated. 
A normal TSH level excludes primary (but not secondary) hypothyroidism. 
If the TSH is elevated, an unbound T4 level is needed to confirm the  presence of 
clinical hypothyroidism, but T4 is inferior to TSH when used as a screening test, 
as it will not detect subclinical or mild hypothyroidism. Circulating unbound T3 
levels are normal in about 25% of patients, reflecting adaptive responses to 
hypothyroidism. T3 measurements are therefore not indicated. 
 
Tests to determine the etiology of thyroid dysfunction 
Once clinical or subclinical hypothyroidism is confirmed, the etiology is 
usually easily established by demonstrating the presence of TPO antibodies, which 
are present in 90 to 95% of patients with autoimmune hypothyroidism. TBII can 
be found in 10 to 20% of patients, but these determinations are not needed 
routinely. If there is any doubt about the cause of a goiter associated with 
 13
hypothyroidism, FNA biopsy can be used to confirm the presence of autoimmnune 
thyroiditis. Other abnormal laboratory findings in hypothyroidism may include 
increased creatine phosphokinase, elevated cholesterol and triglycerides, and 
anemia (usually normocytic or macrocytic). Except when accompanied by iron 
deficiency, the anemia and other abnormalities gradually resolve with thyroxine 
replacement 
 
Radioiodine uptake and thyroid scanning 
The only means of measuring thyroid function directly is by the use of a 
tracer dose of a radioactive isotope of iodine and measurement of its fractional 
uptake by the gland. Following the administration of an oral preparation of 
radiolabelled iodine, a γ-scintillation counter is used to measure radioactivity over 
the area of the thyroid 24 hours later, when the tracer uptake is near maximum. In 
patients with hyperthyroidism, uptake is likely to be higher much earlier and an 
additional measurement is therefore performed at 6 hours. Variations in dietary 
iodine intake will determine the normal range of the radioactive iodine uptake 
within a given population. High values do not always indicate thyroid hormone 
overproduction and caution is required in interpreting the result. 
The efficiency of thyroid organification is examined using the discharge of 
radioactive iodine from the thyroid in response to the administration of potassium 
perchlorate. Two to three hours after an oral dose of radio-iodine, 0.5 g of 
potassium perchlorate is given orally in solution and its effect on radioactive 
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iodine uptake is assessed. In subjects with a normal organification mechanism no 
further uptake of radio-iodine by the thyroid occurs and less than 5 per cent of the 
accumulated iodide is discharged during the succeeding hour. Where an iodide 
organification defect exists, diffusion of iodine out of the thyroid continues and 
this is seen as an increased discharge of radioactivity from the thyroid gland. 
 
Thyroid imaging 
Radionuclide scanning is based on the principle that isotopically labelled 
materials accumulate differentially in thyroid tissue and the detection and 
quantification of this information is transformed into a visual display. This allows 
the localization of functioning and non-functioning thyroid tissue. A number of 
isotopes of iodine and 99Tcm pertechnetate have been used. Because pertechnetate 
is not organified following concentration by the thyroid gland, it diffuses rapidly 
out of the thyroid and this, together with its short physical half-life (6 h), makes 
the radiation delivered to the thyroid, by a standard dose, very low and allows 
imaging 20-30 min after the dose has been given. An important consideration 
when using pertechnetate is that some tumours of the thyroid appear to be 
functioning when examined by pertechnetate but are cold with radio-iodine. 
Improvements in scanning apparatus and in particular the development of the 
pinhole collimated gamma-camera (scintillation), make it possible to scan the 
whole thyroid without moving the camera. This method provides more rapid 
scanning of increased resolution. 
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Thyroid ultrasound 
Ultrasonography of the normal thyroid produces a pattern of sparse, fine 
echoes in the paratracheal region. It is possible to demonstrate diffuse or localized 
enlargement of the gland and provide objective assessments of change in size. The 
sensitivity of the technique allows detection of nodules which are not clinically 
palpable. When these nodules are solitary the significance of their detection in this 
way is as yet unresolved. The major role of ultrasonography is in the 
differentiation of cystic from solid lesions in the thyroid and when a solitary 
nodule can be shown to be purely cystic this considerably reduces the likelihood 
of it being malignant. 
The demonstration by radio-isotope scanning of a solitary cold nodule, 
which is then shown by ultrasonography to be solid, demands further 
investigation. The use in this setting of fine-needle aspiration biopsy coupled with 
cytological examination provides a simple, safe, and rapid means for diagnosis 
and significantly reduces the need for referral for surgical investigation and 
removal. 
 
Peripheral effects of thyroid hormones 
In theory a good test of whether a patient's tissues are being exposed to too 
much or too little thyroid hormone would not be a measurement of circulating 
hormone concentrations but rather a measure of the direct effects of thyroid 
hormones on peripheral tissues. Unfortunately no simple, reproducible, specific, 
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and sensitive test of such effects is available. Such a measure, would be of 
particular value in patients without clinical and biochemical evidence of 
hyperthyroidism but in whom a subnormal TSH or an absent TSH response to 
TRH suggests subnormal thyroid function. In this group of patients two subgroups 
can be discriminated: those in whom the decision concerns whether or not 
treatment of subclinical hypothyroidism might result in benefit, and, in contrast, 
those on replacement thyroxine in whom concerns about over treatment could then 
be more directly addressed.  
Further groups of patients in whom such an approach might contribute to 
management are those presenting with mild hypothyroidism in whom biochemical 
parameters have not been decisively helpful, others with thyroid hormone 
resistance, and those with non-thyroidal illness (the sick euthyroid syndrome). In 
these settings the best established and validated (but also most cumbersome) 
investigation is the basal metabolic rate; the calorigenic effect of thyroid hormones 
increases energy expenditure and heat production. Since heat production cannot be 
measured directly, the test measures oxygen consumption converted into an 
energy equivalent and then related to body surface area. Other tests make use of 
the relationship between muscle relaxation after a contraction and thyroid status 
by measuring the speed of relaxation of the Achilles tendon reflex, which is 
prolonged in hypothyroidism and shortened in hyperthyroidism.  
Tests of myocardial contractility have also been developed and the best 
validated is the measurement of the interval between the initiation of the QRS 
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complex on the electrocardiogram and the arrival of the pulse wave in the brachial 
artery at diastolic pressure (QKd). This is shortened in hyperthyroidism and 
prolonged in hypothyroidism. All three of these measures are altered by a number 
of non-thyroidal states, so that they can only be interpreted with circumspection. 
The serum cholesterol is usually elevated in hypothyroidism and decreased in 
hyperthyroidism and the serum creatinine phosphokinase may be increased in the 
hypothyroid state. It is suggested that absent serum sex hormone binding globulin 
and absent serum ferritin responses to administered thyroxine are likely to be 
associated with generalized resistance to thyroid hormone. 
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HYPOTHYROIDISM 
 
Many structural or functional abnormalities can impair the production of 
thyroid hormones and cause the clinical state termed hypothyroidism. 
 
CAUSES OF HYPOTHYROIDISM 
Primary hypothyroidism with Goiter 
Acquired 
    Hashimoto’s thyroiditis (autoimmune thyroiditis type 2) 
    Iodine deficiency (endemic goiter) 
    Drugs blocking synthesis or release of T4 (lithium, iodide, sulfonamides) 
    Goitrogens in foodstuffs 
    Cytokines (interferon α, interleukin-2) 
    Thyroid infiltration (amyloidosis, hemochromatosis, sarcoidosis, etc.) 
 
Congenital 
    Iodide transport or utilization defect 
    Iodotyrosine dehalogenase deficiency 
    Organification disorders (Thyroid peroxidase deficiency) 
    Defects in thyroglobulin synthesis or processing 
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Atrophic Hypothyroidism 
Acquired 
    Hashimoto’s disease  (autoimmune thyroiditis type 2B) 
    Postablative due to 131I, surgery or irradiation   
Congenital 
    Thyroid agenesis 
    TSH receptor defects 
    Thyroidal Gs protein abnormalities 
    Idiopathic TSH unresponsiveness 
 
Transient Hypothyroidism 
    Following subacute, painless, or post partum thyroiditis 
 
Consumptive Hypothyroidism 
    Rapid destruction of thyroid hormone due to D3 expression in large 
hemangiomas of hemangioendotheliomas 
 
Central hypothyroidism 
Acquired 
    Pituitary origin (secondary) 
    Hypothalamic disorders (tertiary) 
    Dopamine and severe illness 
 20
Congenital 
    TSH deficiency 
    TSH receptor defect 
 
Resistance to thyroid hormone 
    Generalized 
    Pituitary dominant 
 
EPIDEMIOLOGY 
Primary hypothyroidism accounts for approximately 99% of cases, with 
fewer than 1% being due to TSH deficiency. 
Clinically apparent acquired impairment of thyroid function affects about 
2% of adult women and about 0.1 to 0.2% of adult men7,25. Subclinical 
hypothyroidism, an elevated TSH level in an asymptomatic patient, affects 1 to 
10% of adult population, with the highest rate approaching 26% in elderly 
women6,10,11. Neonatal screening programs for congenital hypothyroidism discover 
hypothyroidism in almost 1 in 3500 newborns26. 
 
CLINICAL PRESENTATION 
 Hypothyroidism can affect all organ systems, and these manifestations are 
largely independent of the underlying disorder but are a function of the degree of 
hormone deficiency. 
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Skin and Appendages 
 Hypothyroidism causes an accumulation of hyaluronic acid that alters the 
composition of the ground substance in the dermis and other tissues. This material 
is hygroscopic, producing the mucinous edema that is responsible for the 
thickened features and puffy appearance (myxedema) with full-blown 
hypothyroidism. Myxedematous tissue is characteristically boggy and nonpitting 
and is apparent around the eyes, on the dorsa of the hands and feet, and in the 
supraclavicular fossae. It causes enlargement of the tongue and thickening of the 
pharyngeal and laryngeal mucous membranes. 
The secretions of the sweat glands and sebaceous glands are reduced, 
leading to dryness and coarseness of the skin, which in extreme cases may 
resemble icthyosis. 
Easy bruising occurs due to an increase in capillary fragility. Head and 
body hair becomes dry and brittle, lacks lusterness, and tends to fall out.    
 
Cardiovascular System 
 The cardiac output at rest is decreased because of reduction in both stroke 
volume and heart rate, reflecting loss of the inotropic and chronotropic effects of 
thyroid hormones. Peripheral vascular resistance at rest is increased, and blood 
volume is reduced. These hemodynamic alterations cause narrowing of pulse 
pressure, prolongation of circulation time, and decrease in blood flow to 
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tissues27,28. The decrease in cutaneous circulation is responsible for the coolness 
and pallor of the skin and sensitivity to cold. 
 In severe primary hypothyroidism the cardiac silhouette is enlarged, and the 
heart sounds are diminished in intensity. These findings are the result largely of 
effusion into the pericardial sac of fluid rich in protein and glycosaminoglycans, 
but the “flabby” myocardium may also be dilated 27. 
 Angina pectoris is uncommon, but it may appear or worsen during 
treatment of the hypothyroid state with thyroid hormone27,29,30. There is 
considerable controversy over whether hypothyroidism is a risk factor for 
atherosclerosis. The Whickham Study7 showed no increase in cardiovascular 
mortality in patients with subclinical hypothyroidism over 20 years, whereas the 
Rotterdam Study11 suggested that there was a twofold increase in risk. Systemic 
vascular resistance is increased, and hypertension is more common31. 
 Electrocardiographic changes include sinus bradycardia, prolongation of 
the PR interval, low amplitude of the P wave and QRS complex, alterations of ST 
segment, and flattened or inverted T waves. Pericardial effusion is probably 
responsible for the low amplitude in severe hypothyroidism. Rarely, complete 
heart block may be present, but this disappears when hypothyroidism is treated28. 
 Serum levels of homocysteine, creatine kinase, aspartate aminotransferase 
and lactate dehydrogenase may be increased. 
 The combination of large heart, hemodynamic and electrocardiographic 
alterations, and the serum enzyme changes has been termed myxedema heart. 
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Myxedema heart rarely causes heart failure by itself because the usual 
hemodynamic response to exercise in hypothyroidism is typically normal, 
although exceptions have been reported27,28. 
 
Respiratory System 
 Pleural effusions usually are evident only on radiological examination but 
in rare instances may cause dyspnea. Lung volumes are usually normal, but 
maximal breathing capacity and diffusing capacity are reduced. 
 Obstructive sleep apnea is common but is reversible with restoration of a 
euthyroid state. 
 
Alimentary System 
 Although most patients experience a modest gain in weight, appetite is 
usually reduced. The weight gain that occurs is caused partly by retention of fluid 
by the hydrophilic glycoprotein deposits in the tissues. Peristaltic activity is 
decreased and, together with the decreased food intake, is responsible for the 
frequent complaint of constipation. 
 
 Central and Peripheral Nervous System 
 Thyroid hormone is essential for the development of the central nervous 
system. Deficiency in fetal life or at birth causes retention of the infantile 
characteristics of the brain. If the deficiency is not corrected in early postnatal life, 
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the damage is irreversible. Deficiency of thyroid hormone beginning in adult life 
causes less severe manifestations that usually respond to treatment with the 
hormone.  
 All intellectual functions, including speech, are slowed. Loss of initiative is 
present, slow-wittedness and memory defects are common, lethargy and 
somnolence are prominent, and dementia in elderly patients may be mistaken for 
senile dementia. Psychiatric disorders are common and are usually of the paranoid 
or depressive type and may induce agitation (myxedema  madness)32,33.Epileptic 
seizures have been reported and tend to occur in myxedema coma. 
 Thick, slurred speech and hoarseness are due to myxedematous infiltration 
of the tongue and larynx, respectively. Body movements are slow and clumsy, and 
cerebellar ataxia may occur.  
Numbness and tingling of the extremities are frequent; in the fingers theses 
symptoms may be due to compression by glycosaminoglycan deposits in and 
around the median nerve in the carpal tunnel (carpal tunnel syndrome)34,35. The 
tendon reflexes are slow, especially during the relaxation phase, producing the 
characteristic “hung-up reflexes”; this phenomenon is due to a decrease in the rate 
of muscle contraction and relaxation rather than a delay in nerve conduction. 
 
Muscular System 
 Stiffness and aching of muscles are common and are worsened by cold 
temperatures. Delayed muscle contraction and relaxation cause the slowness of 
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movement and delayed tendon jerks. Muscle mass may be reduced or enlarged due 
to interstitial myxedema. 
 
Skeletal System 
 Thyroid hormone is essential for normal growth and maturation of the 
skeleton, and growth failure is due both to impaired general protein synthesis and 
to a reduction in growth hormone, but especially of insulin-like growth factor I. 
before puberty, thyroid hormone plays a major role in the maturation of bone. 
Deficiency of thyroid hormone in early life leads to both a delay in the 
development of, and an abnormal, stippled appearance of the epiphyseal centers of 
ossification (epiphyseal dysgenesis). Impairment of linear growth leads to 
dwarfism in which the limbs are disproportionately short in relation to the trunk 
but cartilage growth is unaffected. 
Levels of calcium and phosphorus in serum are usually normal, but calcium 
may be slightly elevated 
 
Renal Function 
 Renal blood flow, glomerular filtration rate, and tubular reabsorptive and 
secretory maxima are reduced. Blood urea nitrogen and serum creatinine levels are 
normal, but uric acid levels may be increased. 
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 The impaired renal excretion of water and retention of water by the 
hydrophilic deposits in the tissues result in an increase in total body water, even 
though plasma volume is reduced. 
 
Hematopoietic System 
 In response to the diminished oxygen requirements and decreased 
production of erythropoietin, the red blood cell mass is decreased; this is evident 
in the mild normocytic, normochromic anemia that often occurs. 
 The total and differential white blood cell counts are usually normal, and 
platelets are adequate. 
 
Pituitary and Adrenocortical Function 
 Patients with severe hypothyroidism may have increased serum prolactin 
levels that correlate with the level of serum TSH, and galactorrhea may develop in 
some patients. Treatment with thyroid hormone corrects serum prolactin and TSH 
levels and causes disappearance of galactorrhea, if present. The cause of 
hyperprolactinemia in hypothyroidism is uncertain but may result from enhanced 
sensitivity of the lactotropes to TSH. 
 In severe, long-standing primary hypothyroidism, pituitary and adrenal 
function may be secondarily decreased and adrenal insufficiency may be 
precipitated by stress or by rapid replacement therapy with thyroid hormone. 
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Reproductive Function 
 In adult women, severe hypothyroidism may be associated with diminished 
libido and failure of ovulation. Fertility is reduced, and spontaneous abortion may 
result, although many pregnancies are successful. Hypothyroidism in men may 
cause diminished libido, impotence, and oligospermia.  
 Secretion of progesterone is inadequate and endometrial proliferation 
persists, resulting in excessive and irregular breakthrough menstrual bleeding. 
These changes may be due to deficient secretion of luteinizing hormone. Rarely, in 
primary hypothyroidism, secondary depression of pituitary function may lead to 
ovarian atrophy and amenorrhea. 
 
Energy Metabolism 
 The decrease in energy metabolism and heat production is reflected in the 
low basal metabolic rate, decreased appetite, cold intolerance, and slightly low 
basal body temperature. Both the synthesis and degradation of protein are 
decreased, the latter especially so, with the result that nitrogen balance is usually 
slightly positive. The decrease in protein synthesis is reflected in retardation of 
both skeletal and soft tissue growth. 
 The oral glucose tolerance curve is characteristically flat, and the insulin 
response to glucose is delayed. These alterations may be due to a decreased rate of 
absorption of glucose from gut. Degradation of insulin is slow, so the sensitivity to 
exogenous insulin may be decreased. Increased insulin sensitivity and decrease in 
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appetite presumably account for the decrease in insulin requirement when 
hypothyroidism develops in a patient with preexisting diabetes mellitus. Hepatic 
glycolysis is unaffected by hypothyroidism. 
 Both the synthesis and degradation of lipid are depressed, the latter 
especially so, the net effect being one of lipid accumulation, especially of low-
density lipoprotein (LDL) and triglycerides. High-density lipoprotein (HDL) 
concentrations are reduced. The increase in serum cholesterol in primary (but not 
central) hypothyroidism is accompanied by increased levels of serum 
phospholipids, serum triglycerides, and LDL. 
 The features described above are the consequence of thyroid hormone 
deficiency. However, autoimmune hypothyroidism may be associated with signs 
and symptoms of other autoimmune diseases, particularly vitiligo, pernicious 
anemia, Addison disease, alopecia areata, and type 1 diabetes meelitus. Less 
common associations include celiac disease, dermatitis herpetiformis, chronic 
active hepatitis, rheumatoid arthritis, systemic lupus erythematousus, and 
Sjögrens’s syndrome. Thyroid associated ophthalmopathy, which usually occurs in 
Grave’s disease, occurs in about 5% of patients with autoimmune hypothyroidism. 
 
TREATMENT 
 If there is no residual thyroid function, the daily replacement dose of 
levothyroxine is usually 1.6 µg/kg body weight (typically 100 to 150 µg). In many 
patients, however, lower doses suffice until residual thyroid tissue is destroyed. 
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 Adult patients under 60 years without evidence of heart disease may be 
started on 50 to 100 µg levothyroxine (T4) daily. The dose is adjusted on the basis 
of TSH levels, with the goal of treatment being a normal TSH, ideally in the lower 
half of the reference range. TSH responses are gradual and should be measured 
about 2 months after instituting treatment or after any subsequent change in 
levothyroxine dosage. The clinical effects of levothyroxine replacement are often 
slow to appear. Patients may not experience full relief from symptoms until 3 to 6 
months after normal TSH levels are restored. Adjustment of levethyroxine dosage 
is made in 12.5 or 25 µg increments if the TSH is high; decrements of the same 
magnitude should be made if the TSH is suppressed. 
Particular care is needed in beginning treatment in the elderly and in those 
with a history of heart disease. In patients with coronary artery disease low levels 
of circulating thyroid hormone may protect the heart against increased demands 
that would otherwise result in increasing angina. In such patients appropriate 
therapy for their coronary artery disease should be considered before beginning 
thyroxine. When thyroxine is given, it should be begun at a low dose (25 µg daily 
or on alternate days) and be increased cautiously every 4 weeks until euthyroidism 
is achieved. 
Once full replacement is achieved and TSH levels are stable, follow-up 
measurement of TSH is recommended at annual intervals and may be extended to 
every 2 to 3 years, if a normal TSH is maintained over several years.  
 
 30
MYXEDEMA COMA 
Myxedema coma is an uncommon complication of long-standing 
hypothyroidism and is typically seen in the elderly, often precipitated by severe 
infection, therapy with sedative agents, or by inadequate heating during cold 
weather. It has a high mortality. It is characteristically associated with depression 
of the level of consciousness, and hypothermia. Alveolar hypoventilation leading 
to carbon dioxide retention and a dilutional hyponatremia are often seen.  
Early recognition of the condition and its management are essential. The 
latter is complicated by the sluggish circulation and hypometabolism. General 
supportive measures include intravenous fluids, antibiotics, ventilation, and slow 
rewarming. Thyroid hormone replacement is best given as an intravenous bolus of 
100 µg of T3, because of its rapid action. Thereafter a reasonable dose is 20 µg 
three times a day. It is worth covering the initial treatment period with 
hydrocortisone (100 mg daily) to protect against the possibility of associated 
adrenocortical insufficiency. 
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SUBCLINICAL HYPOTHYROIDISM 
 
 Subclinical hypothyroidism is defined as an isolated elevated serum 
thyrotrophin level in the setting of normal serum thyroid hormone levels, in the 
presence or absence of symptoms4. 
 Although subclinical hypothyroidism is the term most frequently used to 
describe this condition and will be used in this discussion, it is not necessarily apt, 
since on close questioning many patients disclose mild, nonspecific symptoms. 
Mild hypothyroidism may be more appropriate term for this very common 
syndrome. 
 The findings of slightly elevated TSH and normal thyroid hormone levels 
do not necessarily imply the presence of subclinical hypothyroidism. Several 
medications and conditions are known to cause an elevation in TSH. Some drugs   
such as sulfonylureas, lithium, amiodarone, ethionamide,   phenylbutazone, 
aminoglutethimide, and iodine can interfere with thyroid hormone production or 
release and secondarily result in a slight elevation of TSH. In addition, dopamine 
antagonist such as metoclopromide and domperidone may cause exaggerated TSH 
response to TRH stimulation by altering the inhibitory effect of dopamine on TSH 
secretion. Furosemide has also been shown to increase levels of TSH, especially in 
recovering critically ill patients. Other conditions that cause elevated TSH include 
thyroid hormone resistance, thyroid hormone secreting tumors (both should be 
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associated with high free thyroxine level), psychiatric illness, adrenal 
insufficiency, renal failure, hyperprolactinemia and systemic illness36. 
 
PREVALANCE AND NATURAL HISTORY 
Large population studies have suggested that the prevalence of subclinical 
hypothyroidism is much higher in women than men and increases with age. In the 
Whickham survey, TSH levels above 6mIU/l were approximately three times 
more common in females (7.5%) than in males (2.8%) and occurred more 
frequently in females over 45 years of age. TSH levels also showed a progressive 
increase with age in women but not in men37. 
The overall prevalence has been reported to range from 4–10% in large 
general population screening surveys and from 7–26% in studies of the elderly. 
Most studies have shown that subclinical hypothyroidism is more frequent in the 
female sex. A recent study demonstrated a prevalence of elevated TSH in 16% of 
men and 21% of women over age 74 years10,38,39. 
In patients found to have an elevated TSH level, approximately 75% have 
values lower than 10 mIU/L38. Of patients with subclinical hypothyroidism, 
approximately 2% to 5% per year will progress to overt hypothyroidism. Overt 
hypothyroidism is generally defined as a low serum FT4 concentration with 
elevated serum TSH concentration6, but in some cases individuals with 
hypothyroid symptoms and high TSH (>10 mIU/L) with low normal FT4 have 
been among those defined as having overt hypothyroidism7. The rate of 
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progression is proportional to the baseline serum TSH concentration and is higher 
in individuals with antithyroid antibodies7. There is also a strong association 
between positive antithyroid antibodies and elevated TSH. Generally the 
prevalence of elevated TSH levels parallels that of antibody positivity37. A high 
prevalence of antibodies was found in a UK study where antibodies were present 
in 81% of those with TSH concentration over 10 mU/l, 46% of those with TSH 
over 5 mU/l and less than or equal to 10 mU/l and only in 5.7% of those whose 
TSH concentration was less than 0.5 mU/l6. Interestingly, the NHANES III survey 
found a significant association between anti-thyroid peroxidase antibody with 
hypo- or hyperthyroidism but not thyroglobulin antibody.  
After 20 years of follow-up of subjects in the Whickham Survey, the risk of 
overt hypothyroidism was found to be 4.3% per year in women with elevated TSH 
and antithyroid antibodies at baseline. This is a 38 times increased risk over 
normal women. Moreover, an isolated elevation in TSH or presence of antithyroid 
antibodies alone at baseline also conferred an increased risk of overt 
hypothyroidism (2.6% per year and 2.1%per year respectively)7. Progression to 
hypothyroidism was noted to be more common in those with initial TSH value 
greater than 10 mU/l and in those with positive anti-thyroid antibodies6. Huber et 
al found that basal TSH, thyroid reserve (increase in T3 after TRH stimulation) 
and the presence of antimicrosomal antibody are important prognostic factors for 
the development of overt hypothyroidism. Interestingly, antibodies against 
thyroglobulin did not have a predictive value. 
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EFFECTS ON SERUM LIPID LEVELS 
The relationship between mild thyroid failure and reversible elevation in 
serum lipid levels has been widely investigated, but the findings remain 
controversial. Several cross-sectional studies suggest that serum cholesterol 
concentrations are elevated in individuals with mild thyroid failure when 
compared with euthyroid controls40. In other similar studies, however, the 
observed differences between euthyroid and mild hypothyroid individuals have 
not been significant 41.  
The Colorado study which screened 25,862 subjects found that mean total 
cholesterol and low density lipoprotein cholesterol progressively increased with 
increasing serum TSH levels38. A reanalysis by Tanis et al in 1996 found that 
subclinical hypothyroidism was two to three times more frequent in people with 
elevated total plasma cholesterol.  
Thyroid substitution therapy restoring the TSH levels to normal decreased 
total cholesterol by 0.2 to 0.4 mmol/l and mean LDL cholesterol by 0.26mmol/l 
and increased in HDL cholesterol by 0.08 mmol/l while triglycerides, and 
apolipoprotein AI levels remained unchanged. In another study, total cholesterol 
and LDL cholesterol levels decreased only in pretreatment TSH values greater 
than 10 mU/l42. The decrease in total cholesterol and LDL levels with pretreatment 
TSH values greater than 40 mU/l was greater than in those levels between 10 and 
40 mU/l. 
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CARDIAC EFFECTS 
Cardiac changes are evident in subclinical hypothyroidism. These include 
impairment of left ventricular diastolic function at rest (affecting the relaxation of 
the left ventricle and hence ventricular filling), reduced LV systolic function, 
prolongation of pre-ejection time and lastly, impaired intrinsic myocardial 
contractility. There is evidence that these abnormalities improve with L-T4 
treatment, demonstrating that adequate thyroid replacement improves cardiac 
output accompanied by substantial decrease in systemic vascular resistance, a 
reversal of diastolic dysfunction, and importantly an improvement in left 
ventricular ejection fraction during exercise. It has been demonstrated in the 
Rotterdam Study that subclinical hypothyroidism is a strong indicator risk for 
atherosclerosis and myocardial infarction11.  
Inadequately treated hypothyroidism has also been demonstrated to have 
angiographic evidence of coronary atherosclerosis progression. Impairment of 
endothelium-dependent vasodilatation, a harbinger of atherosclerosis, has also 
been detected in patients with subclinical hypothyroidism which can be reversed 
by levothyroxine supplementation. 
 In view of clear structural and biological cardiovascular risks associated 
with the presence of subclinical hypothyroidism, treatment of this condition would 
be expected to provide protection against the development of cardiovascular 
disease, although there have been no long term outcome studies published to date. 
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SOMATIC AND NEUROMUSCULAR EFFECTS 
Patients with subclinical hypothyroidism can have subtle clinical 
manifestations and non-specific symptomatology such as dry skin, cold 
intolerance, constipation, and easy fatigability. In addition, patients with muscular 
symptoms have mitochondrial oxidative dysfunction with significant lactate 
increment during exercise. Misiunas et al also demonstrated the presence of 
subclinical polyneuropathy of probable axonal origin in patients with subclinical 
hypothyroidism43.  
Subclinical hypothyroid subjects reported significantly more total 
symptoms than euthyroid individual in the Colarado study38 and these symptoms 
do improve with L-T4 therapy. The greatest improvement seen is of patients with 
baseline TSH of >12 mU/l. Kong et al observed no improvement in symptoms 
score after trial of thyroxine for six months in patients with TSH level between 5 
and 10 mU/l44.  
Prospective studies suggest that patients with mild thyroid failure have a 
higher prevalence of somatic symptoms, mood disorders, cognitive dysfunction, 
and atypical responses to standard psychiatric therapeutic interventions4. The 
lifetime frequency of depression is significantly higher in patients with subclinical 
hypothyroidism compared with patients with normal thyroid function, suggesting 
that subclinical hypothyroidism lowers the threshold for depression. 
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TREATMENT 
Risks and benefits of treatment 
Among patients with untreated subclinical hypothyroidism, there is no 
single level of serum TSH at which clinical action is always either indicated or 
contraindicated. As the serum TSH concentration increases above 10 mIU/L, 
however, the basis for initiating treatment is more compelling. Clinical context is 
particularly important. This opinion reflects clinical experience and judgment as 
well as the literature that suggests improvement in symptoms and possible 
lowering of LDL cholesterol. There are no studies that demonstrate decreased 
morbidity or mortality with treatment. The potential risks of therapy are limited to 
the development of subclinical hyperthyroidism, which may occur in 14% to 21% 
of individuals treated with levothyroxine.  
 
Subclinical Hypothyroidism with Serum TSH of 4.5 to 10 mIU/L.  
Although some studies suggest an association between subclinical 
hypothyroidism and systemic hypothyroid symptoms38 or cardiac dysfunction15, 
others do not. The available data do not confirm clear-cut benefits for early 
therapy compared with treatment when symptoms or overt hypothyroidism 
develop44. Therefore, routine levothyroxine treatment for patients with TSH levels 
between 4.5 and 10 mIU/L is not recommended, but thyroid function tests should 
be repeated at 6- to 12-month intervals to monitor for improvement or worsening 
in TSH level. 
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Subclinical Hypothyroidism with Serum TSH Higher Than 10 mIU/L  
Levothyroxine therapy is reasonable for patients with subclinical 
hypothyroidism and serum TSH higher than 10 mIU/L. The rate of progression is 
5% in comparison with patients with lower levels of TSH, and treatment may 
potentially prevent the manifestations and consequences of hypothyroidism in 
those patients who do progress. Still, the evidence that therapy will reduce total 
and LDL cholesterol levels and improve symptoms in these patients is 
inconclusive.  
Subclinical Hypothyroidism During Pregnancy 
Pregnant women or women of childbearing potential planning to become 
pregnant who are found to have elevated serum TSH should be treated with 
levothyroxine to restore the serum TSH concentration to the reference range. This 
recommendation is based on the possible association between high TSH and either 
increased fetal wastage or subsequent neuropsychological complications occurring 
in the offspring due to thyroid insufficiency. Although there are no published 
intervention trials assessing the benefits of thyroid hormone replacement in this 
special population, the potential benefit-risk ratio of levothyroxine therapy justifies 
its use. It is important to note that the requirement for levothyroxine in treated 
hypothyroid women frequently increases during pregnancy. Therefore, serum TSH 
concentration should be monitored every 6 to 8 weeks during pregnancy and the 
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levothyroxine dose modified as needed. The risks of appropriately managed 
levothyroxine therapy in pregnancy are minimal.  
Subclinical Hypothyroidism in Treated Overt Hypothyroid Individuals  
When subclinical hypothyroidism is noted in levothyroxine-treated patients 
with overt hypothyroidism, the dosage of levothyroxine should be adjusted to 
bring the serum TSH into the reference range. Whether the target TSH level 
should be in the lower half of the reference range is controversial because there are 
no data demonstrating improved clinical outcomes with this strategy. Nevertheless, 
when the serum TSH is in the upper half of the reference range and levothyroxine-
treated patients continue to note symptoms suggestive of hypothyroidism, it is 
reasonable to increase the levothyroxine dosage to bring the serum TSH into the 
lower portion of the reference range. The rapidity of the dosage adjustment 
depends on the patient's age and medical comorbidities. Minimal TSH elevations 
may not require dosage adjustment in patients who feel well, particularly those 
with arrhythmias or other cardiac disorders.  
To conclude, the patients with serum TSH greater 10mU/l should be treated 
with thyroxine. The AACE has recommended treatment in patients with TSH 
levels between 5 and 10 mU/l in conjunction with a goiter or positive anti-thyroid 
peroxidase antibodies or both and also in the presence of symptoms. If the patients 
are antibody negative and TSH levels are between 5 and 10 mU/l, then an annual 
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check of serum TSH is recommended, with commencement of T4 once the serum 
TSH rises above 10 mU/l. 
 
Arguments against Treatment 
The arguments against treatment are its expense and the likelihood that 
some, or even most, patients will not benefit. There is also a danger of 
overtreatment, which could cause iatrogenic hyperthyroidism and ultimately lead 
to more serious abnormalities (e.g., osteopenia and atrial fibrillation) than leaving 
the subclinical hypothyroidism untreated. Indeed, in one large study, suppressed 
serum thyrotrophin levels consistent with the occurrence of overtreatment were 
found in 21 percent of patients who were taking thyroid hormone38.  
 
THYROXINE THERAPY 
Given the high rate of conversion of subclinical hypothyroidism to overt 
hypothyroidism in the presence of circulating antithyroid antibodies, it makes 
sense to treat asymptomatic persons with positive antibody tests even if they have 
normal serum lipid levels. However, because an elevated serum thyrotrophin level 
is associated with an increased risk of overt hypothyroidism even in the absence of 
antithyroid antibodies, positive antithyroid-antibody titers should not be the sole 
criterion for therapy. It is also reasonable to treat subclinical hypothyroidism in 
pregnant women and in women who have ovulatory dysfunction with infertility.  
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A therapeutic trial for subclinical hypothyroidism is warranted if patients 
have symptoms consistent with the presence of mild hypothyroidism, 
hypercholesterolemia, or a goiter. Although the overlap in symptoms between 
patients with subclinical hypothyroidism and euthyroid persons makes it difficult 
to predict who will have a response to treatment, some patients have a remarkable 
improvement in their symptoms with thyroxine therapy. The positive findings in 
some small clinical trials45,46 also support the use of therapy in symptomatic 
patients, and thyroxine replacement can always be discontinued if there is no 
apparent benefit.  
An initial dose of thyroxine of 0.05 to 0.075 mg per day is usually 
sufficient to normalize the serum thyrotrophin level. Patients with coronary artery 
disease should receive lower initial doses (e.g., 0.0125 to 0.025 mg daily). Serum 
thyrotrophin levels should be measured four to six weeks after therapy is begun, 
after any change in the dose, and then annually once the levels become stable. 
Thyroxine requirements may increase over time if there is progressive thyroid 
failure. Once an elevated serum thyrotrophin level is detected and confirmed, the 
costs of annual follow-up with clinical assessment and laboratory testing are 
relatively similar whether or not patients are treated with thyroxine. Without 
treatment, only 5 percent of elevated serum thyrotrophin levels will revert to 
normal values one year later in older persons. The evidence supports the use of 
treatment for most patients, as long as therapy is monitored with the use of annual 
measurements of serum thyrotrophin. 
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MATERIALS AND METHODS 
Case selection 
 
 Women above the age of 50 years attending the Medical outpatient clinic at 
Stanley Medical College and Hospital, Chennai, from June 2005 to December 
2005 were studied. A sample of 140 women was randomly selected. All the 
participating women were examined for thyroid function. Women with subclinical 
hypothyroidism (defined as TSH > 5.5 µIU/ml with normal free T4 and free T3) 
were considered as cases, and women without subclinical hypothyroidism were 
considered as controls. Laboratory measurements and clinical assessments were 
carried out on all the participants. 
 
Exclusion criteria 
Those with 
• Known thyroid disease 
• History of neck irradiation 
• Chronic renal failure 
• Severe illness (such as infection, recent myocardial infarction, 
severe heart failure, or recent intensive care admission) 
• Taking pharmaceuticals such as beta-blockers, amiodarone, 
interferon-α 
           were excluded. 
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Measurements  
 Thyroid function test - Free T4, free T3, and TSH levels were measured. 
Thyroid function test is done using the electrochemolumences method. The 
normal range for TSH is 0.30-5.50 µIU/ml, for free T4 the normal range is 0.70-
1.80 ng/dL, and for free T3 it is1.70-4.20 pg/ml. 
Clinical assessments 
 Participants with subclinical hypothyroidism were examined for the 
presence of goiter and symptoms of hypothyroidism. 
Analytical methods 
 The following data were collected from the entire study group: 
• Age 
• Presence of Hypertension ( defined as BP >140/90 mmHg on more 
than one occasion, or the patient is known to be hypertensive) 
• Diabetes mellitus (defined as fasting blood sugar >126 mg% on two 
consecutive readings one month apart, or the patient is known to be 
diabetic) 
• Ischemic heart disease (defined as angina or myocardial infarction 
by self report or by analysis of a standard 12 lead ECG) 
Comparison between cases with subclinical hypothyroidism and normal 
control subjects of similar age and ethnic group was done with regard to the 
presence of IHD, hypertension, and diabetes mellitus. 
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Statistical analysis 
Statistical analysis was done using the Statistical Package for Social 
Sciences (SPSS). Different statistical methods were used as appropriate. Mean 
±SD was determined for quantitative data and frequency for categorical variables. 
The independent t-test was performed on all continuous variables. The normal 
distribution of the data was checked before any t-test. The Chi-Square test was 
used to analyze group difference for categorical variables. In logistic regression 
models, age was adjusted for the estimation of each or all the independent effects 
of hypertension, ischemic heart disease, and diabetes. A p-value <0.05 was 
considered significant. 
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RESULTS 
 
 140 women above the age of 50 years who visited the Medical outpatient 
clinic during the study period were studied. 
 41 women were found to have the criteria set for the definition of 
subclinical hypothyroidism, which meant a rate of 29.2%. Patients with subclinical 
hypothyroidism were regarded as cases and the remaining 99 patients were the 
control group. 
 There were differences in the mean age distribution among cases and 
controls. The mean age for patients with subclinical hypothyroidism was 64.7±8.1 
years. The mean age for controls was 63.1±8.8 years. 
 The age distribution of patients (Fig. 1) with subclinical hypothyroidism 
and controls are shown in table 1. 
 
Table 1 
Age Distribution 
Age in years Patients with SH 
[Cases (Total=41)] 
Patients without SH 
[Controls (Total=99)] 
50 – 59 13 41 
60 – 69 15 33 
70 and above 13 25 
                                                                            (SH = Subclinical hypothyroidism) 
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 There were 54 patients in the age group of 50-59 yrs, of which 13 (24%) 
were subclinical hypothyroid patients. In the 60-69 age group there were 48 
patients. The number of subclinical hypothyroid patients were 15 (31.2%). In 
above 70 age group there were 38 patients, of which 13 (34.2%) were having 
subclinical hypothyroidism. 
 The mean TSH level in patients with subclinical hypothyroidism was 11.82 
µIU/ml (Range: 5.81-31.38). For FT4 it was 1.02 ng/dl (Range: 0.72-1.64) and for 
FT3 its 2.63 pg/ml (Range: 1.82-4.02). This is shown in table 2. 
 
Table 2 
 Mean  Range  
TSH (µIU/ml) 11.82 5.81-31.38 
FT4 (ng/dl) 1.02 0.72-1.64 
FT3 (pg/ml) 2.63 1.82-4.02 
(FT3 = Free T3, FT4 = Free T4, TSH = Thyroid Stimulating Hormone) 
 
There were 41 patients with TSH level more than 5.5 µIU/ml, the upper 
level of normal range (0.30-5.5 µIU/ml). They are the subclinical hypothyroid 
patients in this study. Of those 41 patients, 25 (61%) had TSH level between 5.5 to 
10 µIU/ml. The remaining 16 (39%) patients had TSH level more than 10 µIU/ml. 
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The following table shows the TSH levels in patients with subclinical 
hypothyroidism (Fig. 2). 
Table 3 
TSH Levels in Patients with Subclinical Hypothyroidism 
TSH level in µIU/ml No. of patients (%) 
Total no. = 41 
5.5-10 25        (61%) 
>10 16         (39%) 
 
 Hypothyroid symptoms (fig. 3) were reported in 12 of 41 (29%) patients 
with subclinical hypothyroidism. Fatigability was the most common complaint, 
followed by weight gain and constipation, these rates being 10 (24%), 8 (19.5%) 
and 7 (17%) respectively. Other complaints like cold intolerance and infertility 
were less commonly reported. 
 
Table 4 
Frequency of Hypothyroid Symptoms in Patients with SH 
Fatigability  10     (24%) 
Weight gain 8      (19.5%) 
Constipation 7      (17%) 
Others ( Cold intol., Infertility, etc) 8      (19.5%) 
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 Goiter was present in 8 out of 41 patients (Fig. 4) with subclinical 
hypothyroidism (19.5%) and 9 out of 99 patients without subclinical 
hypothyroidism (9%). 
The incidence of risk factors like hypertension, diabetes and ischemic heart 
disease were compared between patients with subclinical hypothyroidism and 
controls (Fig. 5). They were analyzed independently with Chi-Square test. The p-
values showed that patients with subclinical hypothyroidism were significantly 
associated with ischemic heart disease compared to controls. The p-value is not 
significant for hypertension and diabetes. This is shown in the table below. 
 
Table 5 
 
 
  
Patients with  SH Patients without SH  
N % N % 
p-value 
HT 
  
11 26.8% 25 25.3% 0.85 
DM 
  
9 22.0% 21 21.2% 0.93 
IHD 
  
9 22.0% 9 9.1% 0.04 
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After taking all the above risk factors into consideration in multiple 
regression, p-value is still significant for ischemic heart disease alone. This is 
shown in the following table. 
 
Table 6 
95% Confidence Interval  Odd Ratio 
Lower Upper 
p - value 
HT 1.162 0.496 2.722 0.730 
DM 0.676 0.246 1.862 0.449 
IHD 3.398 1.101 10.493 0.033 
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DISCUSSION 
 
 Subclinical hypothyroidism is highly prevalent in elderly women. A 
prevalence of 11–26% had been reported in previous studies6, 12, 38, 47, while our 
study showed that 29.2% of the elderly women above the age of 50 years 
attending the outpatient clinic had subclinical hypothyroidism. This higher 
prevalence in our population could be due to environmental or genetic factors, 
which should be verified in further studies. 
Surveys that stratified TSH levels indicate a predominance of TSH <10 
µIU/ml, which accounts for 55–85% of cases5,7,48. Almost 61% of our patients 
with subclinical hypothyroidism had TSH <10 µIU/ml. Studies that have reported 
thyroid antibody test on subjects with elevated TSH demonstrated seropositivity 
rates from 20–78%6,9,10,49.  
Goiter is twice as prevalent among patients with subclinical 
hypothyroidism10. It is found in 19.5% of our patients with subclinical 
hypothyroidism as against 9% in controls. 
Several studies have suggested that mild symptoms of hypothyroidism are 
more prevalent in patients with subclinical hypothyroidism than in age-matched 
controls38,49; fatigability and weight gain were the most frequent44, but not all 
studies have found this to be true51. Twenty-nine percent of our patients with 
subclinical hypothyroidism had symptoms, fatigability being the most common. 
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There have been three published randomized prospective placebo-controlled trials 
on the therapy of symptoms in patients with subclinical hypothyroidism45,52,53. 
Two trials reported significant improvement in the symptoms of hypothyroidism, 
whereas the third found no benefit of therapy45,52,53. The benefit of therapy was 
related to TSH level, being more in those whose mean serum TSH was 12.7 mU/l 
at base line52. In women with SH and ovulatory dysfunction, thyroxine therapy 
may restore fertility54.  
Case control and cross-sectional studies on the association between 
subclinical hypothyroidism and cardiovascular diseases have been done, but 
results were controversial10,12,18,55-57. A 20- year follow-up study of the original 
Whickham survey58 showed no association between elevated TSH and increased 
risk of IHD, while a report of 1149 women from Rotterdam showed increased 
atherosclerotic vascular disease and myocardial infarction in patients with 
subclinical hypothyroidism12. The present study showed a significant increase in 
IHD in patients with subclinical hypothyroidism compared with controls (P value 
0.033). Several studies on the association between subclinical hypothyroidism and 
dyslipidemia have been done. The initial Whickham study observed that lipid 
levels were not associated with TSH elevation after age adjustment10. The 
Colorado study and others noted significantly elevated LDL cholesterol in subjects 
with subclinical hypothyroidism16,38. A report from Rotterdam noted that 
subclinical hypothyroidism subjects actually had lower total cholesterol12.  
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Women with subclinical hypothyroidism did not differ from controls with 
regard to hypertension, and diabetes in the previous studies12,51. The present study 
also showed it to be true. 
A recent analysis concluded that screening for and treating mild thyroid 
failure in all adults over 35 years of age is as cost-effective as many other 
screening procedures59. There is documented evidence that many (but not all) 
effects are improved or corrected when L-thyroxine replacement is instituted. L-
thyroxine treatment was recommended for the majority of patients with mild 
thyroid failure, particularly those with symptoms, goiter, positive thyroid 
antibodies, and those who are pregnant. However, despite these positive 
indications that treatment carries some benefits, the benefit-to-risk ratio of 
treatment remains to be determined, given the lack of outcome data and the 
considerable risk of TSH suppression in patients on L-thyroxine replacement.  
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CONCLUSION 
  
 Subclinical hypothyroidism is highly prevalent in elderly women 
above the age of 50 years (29.2%). Most of those with subclinical 
hypothyroidism have the TSH level below 10 µIU/ml. 
 Mild symptoms of hypothyroidism are prevalent in patients with 
subclinical hypothyroidism (29% of patients in this study).  
Fatigability being the most common symptom. 
 Patients with subclinical hypothyroidism are more prone to develop 
ischemic heart disease. 
 There is no increased risk for developing hypertension and diabetes 
mellitus in patients with subclinical hypothyroidism. 
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PROFORMA 
NAME:                                                                IP NO: 
AGE:                                                                    ADDRESS: 
SEX:                                                                     OCCUPATION: 
HISTORY OF 
• Fatigability 
• Weight gain 
• Constipation 
• Cold intolerance 
PAST HISTORY: 
• Hypertension 
• Diabetes mellitus 
• Coronary heart disease 
• Hypothyroidism  
• Drug intake 
• Exposure to irradiation 
• Thyroid surgery 
PERSONAL HISTORY: 
1. Menstrual history 
2. Obstetric history 
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CLINICAL EXAMINATION: 
          Pulse rate                           Blood pressure                       Goiter 
CVS: 
RS: 
ABDOMEN: 
CNS: 
INVESTIGATION: 
• FT3, FT4, TSH 
• Fasting blood sugar 
• ECG 
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MASTER CHART 
 
PATIENTS WITH SUBCLINICAL HYPOTHYROIDISM 
 
 
S. N    S.NO AGE FT3 FT4 TSH HT DM IHD FATIGA
BILITY 
CONSTI 
PATION 
WEIGHT 
GAIN 
OTHER 
SYMPTOMS 
GOITER 
1 55 3.42 0.72 14.84 + - + - - - - - 
2 64 1.96 0.78 9.4 - - - - - - - - 
3 61 2.2 1.12 8.04 - - - - - - - + 
4 65 1.96 0.88 13.5 + - - - - - - - 
5 58 2.46 0.96 7.04 - + + - - - - - 
6 73 3.96 0.8 6.21 + - - - - - - - 
7 53 3.64 0.98 8.92 - - - - - - - - 
8 64 3.2 0.84 10.82 - - - + - + + - 
9 55 2.24 1.24 9.02 - - - - - - - - 
10 75 3.26 0.88 7.72 - + + - - - - - 
11 63 3.12 0.96 15.42 + - - + + + + + 
12 54 2.36 0.92 8.48 - - - - - - - - 
13 77 3.44 1.34 7.62 - - + - - - - - 
14 58 2.44 1.64 8.26 - - - - - - - + 
15 79 3.26 1.24 31.33 + + - - + + + - 
16 57 3.38 0.92 7.62 - - - - - - - - 
17 71 3.86 0.78 6.9 - - - - - - - - 
18 66 4.02 1.24 19.17 - - + - - - - - 
19 52 3.32 1.44 9.24 + + - - - - - - 
20 74 3.24 1.42 20.36 - - - + + + - + 
S. N    S.NO AGE FT3 FT4 TSH HT DM IHD FATIGA
BILITY 
CONSTI 
PATION 
WEIGHT 
GAIN 
OTHER 
SYMPTOMS 
GOITER 
21 57 2.1 1.4 8.46 - - - - - - - - 
22 62 3.7 1.46 13.93 - + + - - - - - 
23 67 2.68 0.88 17.5 - - - - - - - - 
24 58 3.28 0.92 8.4 - - - - - - - - 
25 76 1.92 0.88 12.62 - - - + + - + + 
26 65 1.96 0.96 9.38 - - - - - - - - 
27 73 1.88 0.92 28.82 + + - + + + - - 
28 59 2.08 0.98 8.42 + + - - - - - - 
29 61 1.82 0.96 31.38 + - - + + - + - 
30 51 2.22 0.86 9.4 - - + - - - - - 
31 66 3.26 1.14 7.62 - - - - - - - - 
32 67 1.98 1.02 5.81 - + - - - - - - 
33 72 1.88 0.92 11.23 - - - + + - + + 
34 70 2.12 0.94 7.86 - - - - - - - - 
35 53 1.92 0.88 9.22 - - - - - + + - 
36 60 1.82 0.82 16.23 - - - + - + - + 
37 68 1.92 0.98 8.32 - + + - - - - - 
38 76 2.26 0.92 7.64 - - - - - - - - 
39 78 2.08 0.96 9.86 - - - - - - - - 
40 69 2.18 0.92 11.72 + - - + - - - + 
41 72 2.14 0.84 10.86 + - + + - + + - 
 
 
 
 
 PATIENTS WITHOUT SUBCLINICAL HYPOTHYROIDISM 
 
S. NO AGE FT3 FT4 TSH HT DM IHD GOITER 
1 65 2.48 0.82 4.6 - - - - 
2 62 4.1 1.62 3.82 - - - - 
3 52 3.24 1.04 4.16 - + - - 
4 71 1.84 1.24 5.12 - - - + 
5 58 2.6 1.54 3.44 + - - - 
6 72 2.24 0.94 4.6 - - - - 
7 66 3.72 0.82 2.18 + - - - 
8 77 3.4 1.62 4.72 + + - - 
9 68 3.42 1.42 4.24 + - - + 
10 51 3.12 0.9 2.86 - - - - 
11 67 2.88 1.24 5.12 - - - - 
12 76 3.4 1.32 4.76 - - - - 
13 52 4.04 0.92 3.53 - - - - 
14 78 2.62 0.92 2.08 + - + - 
15 53 1.94 0.92 4.81 - - - - 
16 79 1.88 0.88 3.6 - - - - 
17 59 2.42 1.12 3.14 - - - - 
18 69 3.12 1.06 4.88 - + - - 
19 74 1.96 1.32 3.86 - - - - 
20 69 2.4 0.96 2.62 + - - + 
21 52 2.42 0.82 3.6 - - - - 
22 60 2.26 1.06 2.06 - + + - 
23 78 1.94 1.28 5.32 - - - - 
S. NO AGE FT3 FT4 TSH HT DM IHD GOITER 
24 56 2.82 0.98 3.22 - - - - 
25 73 2.64 0.82 2.76 - + + - 
26 66 2.92 1.08 5.12 - - - - 
27 68 3.68 1.32 4.66 - - - - 
28 52 1.88 1.12 3.42 - - - - 
29 57 3.34 1.32 2.74 + - - - 
30 61 3.94 0.86 0.92 - - - - 
31 75 3.88 0.92 4.78 - - - - 
32 67 2.68 1.32 5.44 - - - - 
33 70 2.94 0.88 1.68 + - - - 
34 51 2.62 1.16 4.08 - + + - 
35 62 3.42 0.88 0.98 - - - - 
36 78 3.88 0.86 3.28 - - - - 
37 57 2.68 0.98 4.3 - - - - 
38 56 3.54 0.92 5.14 + - - - 
39 69 2.82 1.62 4.5 - - - - 
40 71 1.96 1.34 2.68 - - - - 
41 75 3.32 0.76 4.86 - - - - 
42 51 2.84 0.88 3.8 - + - - 
43 63 2.76 1.16 4.36 + - - - 
44 79 3.4 1.08 1.6 - - - + 
45 56 1.96 0.94 3.42 - - - - 
46 55 2.88 0.86 2.88 - - - - 
47 68 3.92 1.6 4.24 - + - - 
48 72 4.02 1.56 2.24 + + - + 
49 59 3.24 1.42 3.62 - - - - 
S. NO AGE FT3 FT4 TSH HT DM IHD GOITER 
50 64 2.46 1.08 4.48 - - - - 
51 51 4.08 0.98 4.6 - - - - 
52 73 3.88 1.24 2.74 - + + - 
53 54 2.92 1.12 4.15 + + - - 
54 65 3.76 1.46 4.26 - - - - 
55 76 2.96 0.96 5.16 - - - - 
56 66 2.14 0.98 4.44 - - - - 
57 53 3.82 1.16 2.24 - + + - 
58 51 2.76 1.24 3.08 - + - - 
59 55 3.34 0.96 4.72 - - - - 
60 58 2.86 1.32 3.68 - - - - 
61 66 3.62 1.44 2.72 - - - - 
62 74 3.82 1.08 2.86 - - - - 
63 50 1.96 1.26 3.82 - - - - 
64 53 2.42 1.06 2.94 - - - - 
65 65 3.32 1.18 3.46 + - - - 
66 52 3.82 0.96 4.34 + - - - 
67 75 3.66 1.32 2.44 + + - - 
68 67 1.88 1.46 3.38 - - - + 
69 57 2.6 1.22 5.22 + - - - 
70 67 1.86 1.24 4.84 - + + - 
71 51 2.42 1.42 4.26 + - - - 
72 76 3.26 1.34 1.56 - - - - 
73 73 3.34 1.12 5.2 - - - + 
74 50 3.26 0.98 4.72 - - - - 
75 63 4.04 0.88 2.64 - - - - 
S. NO AGE FT3 FT4 TSH HT DM IHD GOITER 
76 56 3.62 1.42 3.82 - - - - 
77 69 2.14 1.08 4.46 - + + - 
78 77 3.26 1.26 2.74 + - - - 
79 54 3.82 1.18 3.62 - + - - 
80 68 2.68 1.22 5.4 - - - - 
81 59 2.84 1.64 3.76 + - - - 
82 64 2.26 1.42 5.18 + - + + 
83 55 3.42 1.18 1.12 - - - - 
84 51 3.84 0.98 2.32 - - - - 
85 63 1.96 1.42 3.28 - - - - 
86 54 2.24 1.36 4.76 - - - - 
87 78 3.62 1.06 1.86 + + - - 
88 58 3.44 0.92 2.38 + - - - 
89 60 2.84 1.04 3.82 + - - - 
90 55 3.26 1.22 4.4 - - - + 
91 52 2.98 1.42 1.24 - - - - 
92 53 3.28 1.18 4.68 - - - - 
93 74 2.24 0.82 3.56 - - - - 
94 58 3.42 1.24 5.24 - - - - 
95 64 2.98 1.38 3.86 + + - - 
96 61 3.12 0.98 4.24 - - - - 
97 56 2.96 1.4 1.74 + + - - 
98 65 3.4 1.28 3.64 - + - - 
99 62 3.62 1.14 3.8 - - - - 
 
